The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

The Food and Drug Administration (FDA) approved a weight-loss drug to ... moderate-to-severe OSA and aids in long-term weight loss in adults with obesity,” the president of Lilly Cardiometabolic ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The Food and Drug Administration has approved ... Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss ...

The approval supports evidence that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease risk. Other studies are ...

The move comes as weight-loss ... when the FDA approved Wegovy for cardiovascular disease risk reduction early in 2024,” Juliette Cubanski, a deputy director of KFF, a nonpartisan health-care ...

The weight loss ... FDA's Center for Drug Evaluation and Research, in a statement. The federal approval does not come as a complete surprise, as doctors have long recommended that maintaining a ...

The U.S. Food and Drug Administration (FDA ... improving overall health. The approval of Zepbound underscores the evolving landscape of OSA management, combining weight-loss benefits with improved ...